Swedish Orphan Biovitrum Release: Kiobrina Pivotal Phase 3 Study Did Not Meet Primary Endpoint

STOCKHOLM, March 26, 2014 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announced topline data from the company's pivotal phase 3 study of its enzyme therapy Kiobrina (rhBSSL - recombinant human Bile Salt Stimulated Lipase). The primary endpoint of the study - growth velocity measured after four weeks of treatment with rhBSSL - was not met. No statistically significant improvement in growth velocity was demonstrated in preterm infants treated with rhBSSL compared to placebo.

Help employers find you! Check out all the jobs and post your resume.